




## Supplementary Figures




**Supplementary Figure 1. Macrophages are highly pinocytic *in vivo*.** G-KO mice were injected (i.v.) with 1.5 mg hIgG1<sup>D265A</sup>, followed by perfusion and organ collection 10 hours later. Colocalization of the injected antibody (pseudocolored green) with F4/80<sup>+</sup> macrophages or CD31<sup>+</sup> endothelial cells (pseudocolored red) is shown. Representative cells (boxed) are cropped and expanded in the panels on the right hand side. Scale bars = 30  $\mu$ m, and for expanded images, scale bars = 10  $\mu$ m. Data shown is derived from immunohistochemical analyses of two mice from two independent experiments ( $\geq 51$  images were acquired per tissue).



**Supplementary Figure 2. Analysis of accumulation of IgG and secondary antibody staining/background autofluorescence levels in skin, muscle, intestine and liver.** G-KO mice were treated as in Supplementary Figure 1. Endothelial cells (CD31<sup>+</sup>; pseudocolored red), injected antibody (pseudocolored green) and secondary antibody staining/background autofluorescence levels (2<sup>o</sup>; pseudocolored red/green) are shown. Scale bars = 30  $\mu$ m. Data shown is derived from immunohistochemical analyses of two mice from two independent experiments ( $\geq 51$  images were acquired per tissue).




**Supplementary Figure 3. Analysis of accumulation of IgG and secondary antibody staining/background autofluorescence levels in lung and kidney.** G-KO mice were treated as in Supplementary Figure 1. Injected antibody (pseudocolored green), macrophages (F4/80<sup>+</sup>, pseudocolored red), endothelial cells (CD31<sup>+</sup>; pseudocolored red) and secondary antibody staining/background autofluorescence levels (2°; pseudocolored red/green) are shown. Scale bars = 30  $\mu$ m. Data shown is derived from immunohistochemical analyses of two mice from two independent experiments ( $\geq 46$  images were acquired per tissue).




**Supplementary Figure 4. Analysis of accumulation of IgG and secondary antibody staining/background autofluorescence levels in spleen and lymph nodes.** G-KO mice were treated as in Supplementary Figure 1. Injected antibody (pseudocolored green), macrophages (F4/80<sup>+</sup>, pseudocolored red), endothelial cells (CD31<sup>+</sup>; pseudocolored red) and secondary antibody staining/background autofluorescence levels (2°; pseudocolored red/green) are shown. Scale bars = 30  $\mu$ m. Data shown is derived from immunohistochemical analyses of two mice from two independent experiments ( $\geq 78$  images were acquired per tissue).






**Supplementary Figure 5. MST-HN accumulation in cells is dependent on FcRn expression levels.** Human endothelial cells (HMEC-1) were co-transfected with expression plasmids encoding either mFcRn-GFP and m $\beta_2$ m or hFcRn-L136-GFP and h $\beta_2$ m. Untransfected HMEC-1 cells were used as controls. The cells were incubated with Alexa 647-labeled MST-HN, H435A or vehicle at 37 °C to assess FcRn-mediated uptake of fluorescently-labeled antibodies. Levels of cell-associated fluorescence were determined using flow cytometry. Each experiment was carried out using triplicate samples and one representative flow cytometry plot for each transfection or treatment condition is shown. mFcRn-GFP, mouse FcRn tagged with enhanced green fluorescent protein; m $\beta_2$ m, mouse  $\beta_2$ -microglobulin; hFcRn-L136-GFP, mutated human FcRn tagged with enhanced green fluorescent protein; h $\beta_2$ m, human  $\beta_2$ -microglobulin; MST-HN, mutated human IgG1 with increased affinity for FcRn;<sup>1</sup> H435A, mutated, control human IgG1 with negligible binding for FcRn.<sup>2</sup> Data shown is representative of two independent experiments.




**Supplementary Figure 6. CD11c-Cre-mediated deletion of FcRn in CD11c-Cre-FcRn<sup>flx/flx</sup> mice is not restricted to DCs.** Splenocytes were isolated, pooled (from 2-3 mice/genotype) and incubated with anti-FcγRIIB/III (2.4G2) antibody at 4 °C followed by Alexa 647-labeled MST-HN or H435A mutant at 37 °C to assess FcRn-mediated uptake. Fluorescence levels associated with each of the indicated cell types were determined using flow cytometry. Macrophages and DCs were identified as F4/80<sup>bright</sup>CD11b<sup>low</sup> and CD11c<sup>+</sup>CD11b<sup>+</sup>, respectively. The gating strategies employed for the identification of these cell types are shown in Supplementary Fig. 8A and B. CD11c-KO, CD11c-Cre-FcRn<sup>flx/flx</sup>; CD11c-Het, CD11c-Cre-FcRn<sup>flx/+</sup>; MST-HN, mutated human IgG1 with increased affinity for FcRn;<sup>1</sup> H435A, mutated (control) human IgG1 with negligible binding towards FcRn.<sup>2</sup> Data shown is representative of at least two independent experiments.




**Supplementary Figure 7. Loss of FcRn function in B cells and dendritic cells does not affect serum IgG levels.** Serum IgG levels in B-DC-KO and B-DC-Het mice are shown. Error bars indicate SEM. N.S., no significant difference ( $p > 0.05$ ; two-tailed Student's  $t$ -test). B-DC-KO, CD19-Cre-FcRn<sup>fllox/fllox</sup> (B cell- and DC-specific FcRn KO); B-DC-Het, CD19-Cre-FcRn<sup>fllox/+</sup> (control). Data shown is derived from 17-23 mice/genotype.





**Supplementary Figure 8. Gating strategy used for analyzing functional FcRn levels in different immune cell types.** Gating strategy used to identify splenic macrophages (A), monocytes (A), neutrophils (A), classical DCs (B), follicular B cells (C) and macrophage subtypes (D) in kidney, lung and liver is shown.



**Supplementary Figure 9. Gating strategy employed for analyzing functional FcRn levels in endothelial cells and percentage of macrophages.** Gating strategy employed to identify endothelial cells in the heart (A) and lung (B), and macrophage subtypes in the spleen (C) and liver (D) of liposome-treated mice is shown.

## REFERENCES

1. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate *in vivo* antibody levels. *Nat Biotechnol.* 2005;23(10):1283-1288.
2. Firan M, Bawdon R, Radu C, Ober RJ, Eaken D, Antohe F, Ghetie V, Ward ES. The MHC class I related receptor, FcRn, plays an essential role in the maternofetal transfer of gammaglobulin in humans. *Int Immunol.* 2001;13:993-1002.